NASDAQ:SAGE

Sage Therapeutics Stock Forecast, Price & News

$43.33
-1.01 (-2.28 %)
(As of 07/27/2021 04:41 PM ET)
Add
Compare
Today's Range
$42.85
$44.55
50-Day Range
$44.34
$79.11
52-Week Range
$42.85
$98.39
Volume1.01 million shs
Average Volume660,408 shs
Market Capitalization$2.53 billion
P/E Ratio3.64
Dividend YieldN/A
Beta1.99
30 days | 90 days | 365 days | Advanced Chart
Receive SAGE News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Sage Therapeutics logo

About Sage Therapeutics

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.64 out of 5 stars

Medical Sector

15th out of 2,218 stocks

Pharmaceutical Preparations Industry

7th out of 869 stocks

Analyst Opinion: 4.2Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Sage Therapeutics (NASDAQ:SAGE) Frequently Asked Questions

Is Sage Therapeutics a buy right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last twelve months. There are currently 10 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Sage Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View analyst ratings for Sage Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Sage Therapeutics?

Wall Street analysts have given Sage Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sage Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Sage Therapeutics' next earnings date?

Sage Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Sage Therapeutics
.

How can I listen to Sage Therapeutics' earnings call?

Sage Therapeutics will be holding an earnings conference call on Tuesday, August 3rd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) posted its quarterly earnings results on Tuesday, May, 4th. The biopharmaceutical company reported ($1.64) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.98) by $0.34. The biopharmaceutical company earned $1.58 million during the quarter, compared to analyst estimates of $2.03 million. Sage Therapeutics had a net margin of 57.21% and a negative trailing twelve-month return on equity of 32.31%. The company's revenue was down 30.8% on a year-over-year basis. During the same quarter in the prior year, the business posted ($2.44) EPS.
View Sage Therapeutics' earnings history
.

How has Sage Therapeutics' stock price been impacted by Coronavirus?

Sage Therapeutics' stock was trading at $42.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SAGE stock has increased by 2.4% and is now trading at $43.32.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for SAGE?

17 analysts have issued 12-month target prices for Sage Therapeutics' stock. Their forecasts range from $62.00 to $102.00. On average, they anticipate Sage Therapeutics' share price to reach $83.65 in the next twelve months. This suggests a possible upside of 93.1% from the stock's current price.
View analysts' price targets for Sage Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Sage Therapeutics' key executives?

Sage Therapeutics' management team includes the following people:
  • Barry E. Greene, President, Chief Executive Officer & Director
  • Kimi E. Iguchi, Chief Financial Officer & Treasurer
  • Al Robichaud, Chief Scientific Officer
  • Jim Doherty, Chief Research Officer
  • Steve Kanes, Chief Medical Officer

Who are some of Sage Therapeutics' key competitors?

What other stocks do shareholders of Sage Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

What is Sage Therapeutics' stock symbol?

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

Who are Sage Therapeutics' major shareholders?

Sage Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.02%) and Cooper Financial Group (0.01%). Company insiders that own Sage Therapeutics stock include Albert Robichaud, Barry E Greene, James M Frates and Jeffrey M Jonas.
View institutional ownership trends for Sage Therapeutics
.

Which institutional investors are buying Sage Therapeutics stock?

SAGE stock was bought by a variety of institutional investors in the last quarter, including Cooper Financial Group, and State of Alaska Department of Revenue. Company insiders that have bought Sage Therapeutics stock in the last two years include Albert Robichaud, Barry E Greene, James M Frates, and Jeffrey M Jonas.
View insider buying and selling activity for Sage Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Sage Therapeutics?

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sage Therapeutics' stock price today?

One share of SAGE stock can currently be purchased for approximately $43.32.

How much money does Sage Therapeutics make?

Sage Therapeutics has a market capitalization of $2.53 billion and generates $1.11 billion in revenue each year. The biopharmaceutical company earns $606.07 million in net income (profit) each year or ($9.47) on an earnings per share basis.

How many employees does Sage Therapeutics have?

Sage Therapeutics employs 298 workers across the globe.

What is Sage Therapeutics' official website?

The official website for Sage Therapeutics is www.sagerx.com.

Where are Sage Therapeutics' headquarters?

Sage Therapeutics is headquartered at 215 FIRST STREET, CAMBRIDGE MA, 02142.

How can I contact Sage Therapeutics?

Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at (617) 299-8380 or via email at [email protected]


This page was last updated on 7/27/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.